In-Depth Mapping of the Urinary N-Glycoproteome: Distinct Signatures of ccRCC-related Progression

Protein N-glycosylation is one of the most important post-translational modifications and is involved in many biological processes, with aberrant changes in protein N-glycosylation patterns being closely associated with several diseases, including the progression and spreading of tumours. In light o...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 12; no. 1; p. 239
Main Authors Santorelli, Lucia, Capitoli, Giulia, Chinello, Clizia, Piga, Isabella, Clerici, Francesca, Denti, Vanna, Smith, Andrew, Grasso, Angelica, Raimondo, Francesca, Grasso, Marco, Magni, Fulvio
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 18.01.2020
MDPI
Subjects
Online AccessGet full text
ISSN2072-6694
2072-6694
DOI10.3390/cancers12010239

Cover

More Information
Summary:Protein N-glycosylation is one of the most important post-translational modifications and is involved in many biological processes, with aberrant changes in protein N-glycosylation patterns being closely associated with several diseases, including the progression and spreading of tumours. In light of this, identifying these aberrant protein glycoforms in tumours could be useful for understanding the molecular mechanism of this multifactorial disease, developing specific biomarkers and finding novel therapeutic targets. We investigated the urinary N-glycoproteome of clear cell renal cell carcinoma (ccRCC) patients at different stages (n = 15 at pT1 and n = 15 at pT3), and of non-ccRCC subjects (n = 15), using an N-glyco-FASP-based method. Using label-free nLC-ESI MS/MS, we identified and quantified several N-glycoproteins with altered expression and abnormal changes affecting the occupancy of the glycosylation site in the urine of RCC patients compared to control. In particular, nine of them had a specific trend that was directly related to the stage progression: CD97, COCH and P3IP1 were up-expressed whilst APOB, FINC, CERU, CFAH, HPT and PLTP were down-expressed in ccRCC patients. Overall, these results expand our knowledge related to the role of this post-translational modification in ccRCC and translation of this information into pre-clinical studies could have a significant impact on the discovery of novel biomarkers and therapeutic target in kidney cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
These authors contributed equally to this paper.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers12010239